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Aberrant actomyosin interactions contribute to awide range of pathophysiological conditions including heart
failure, neurodegenerative disorders, and tumor growth. Despite surgical, interventional, and pharmacolog-
ical advances, the burden and economic impact of these diseases remains immense. The initiation and
progression of these disorders is frequently found to be a direct consequence of aberrant motile activity,
which makes the in-depth investigation of the molecular mechanisms underlying actomyosin-dependent
motility a prerequisite for the development of innovative treatment strategies. The present review describes
key structural features of the actomyosin system, the basis of chemo-mechanical and allosteric coupling in
the myosin motor domain, and molecular engineering and small molecule-based approaches to alter myosin
function.Structural Features of Actomyosin
All our movements, each step and every heartbeat, require a
force generating interaction between ropes formed by the
motor protein myosin and filaments formed by the cytoskeletal
protein actin. On the cellular level, the interaction between
myosin and actin is essential for embryogenesis and develop-
ment as it drives the machinery that pinches cells apart during
cell division, enables cells to move and change shape, mediates
themechanical gating of stretch-activated ion channels, enables
structural changes of neurons after learning or plastic changes
after a stroke, and supports the active transport of vesicles, or-
ganelles, and RNAs in the cytoplasm. The founding members
of the myosin superfamily are class 2 or conventional myosins.
In mammals, there are 15 genes encoding myosin-2 heavy
chains (MHC-2). They are among the most abundant proteins,
as they constitute the primary contractile element in the sarco-
meres of skeletal, smooth, and cardiac muscles. However, their
localization is not restricted to sarcomeric structures. They play a
critical role in generating and sensing mechanical forces and in
driving other motile events in muscle and nonmuscle cells.
Myosin-2 is formed of six polypeptide chains, two MHC-2, and
two pairs of distinct light chains (LC). The architecture of this
hexamer is highly asymmetric. Each MHC-2 consists of an
N-terminal head region, which is the common element found in
all members of the myosin family (Odronitz and Kollmar, 2007).
The globular part of the head region (780 amino acids) is also
referred to as motor domain, as it contains the actin and nucle-
otide binding sites and is sufficient to move actin filaments
in vitro (Manstein et al., 1989; Toyoshima et al., 1987).
Generic myosin motor domains are primarily built of a helices
arranged around a seven-stranded b sheet core, the so-called
transducer (Rayment et al., 1993b; Sweeney and Houdusse,
2010). Differences between the motor domains from different
isoforms are mostly restricted to the nature of side chains in
less-well conserved regions and the length and composition of
surface loops. However, loop regions that control functional
features, such as actin binding and nucleotide binding, appear
to be actually more constrained than the sequences of the restStructureof the myosin molecule (Goodson et al., 1999). Although the
motor domain is structurally conserved throughout the myosin
superfamily, critical features of the motor such as the ability
to produce force and movement against an external load, pro-
cessivity of movement, and the regulation of motor activity by
ion binding or posttranslational modifications can differ greatly
between myosin isoforms (Hartman et al., 2011).
Four structural subdomains can be distinguished, the
N-terminal subdomain, the upper (U50) and lower (L50) 50 kDa
subdomains, and the converter (Figure 1). The absence of an
SH3-like N-terminal subdomain in myosin 1 and deletion studies
withmyosin 2 indicate that this subdomain is not required to sup-
port myosin motor activity (Kollmar et al., 2002). Possible func-
tions include a role in mediating communication between the
active site and the light chain binding region and a modulating
effect on nucleotide turnover, stiffness, and protein stability
(Fujita-Becker et al., 2006). A prominent feature of themyosinmo-
tor domain is the large cleft that separates the U50 and L50 (Ray-
ment et al., 1993b). The active site with its three highly conserved
nucleotide-binding motifs: the P loop, Switch-1, and Switch-2 is
located close to the apex of the large cleft and near the interface
between the U50 and L50. Comparison of structures solved in
the absence and presence of nucleotide analogs confirmed that
these nucleotide-binding loops are subject to conformational
changes, similar to the nucleotide-dependent opening and
closing of switches in the structurally related G-proteins (Goody
and Hofmann-Goody, 2002; Reubold et al., 2003). At the distal
end of the cleft, the strut and loop 2 pass from the L50 across
the cleft and back, holding a helix-loop-helix motif attached to
the outer face of the U50 (Figure 1). The converter domain acts
as a socket for the lever arm and rotates by 60 during force
generation, leading to a large swinging of the lever arm. The
asymmetric connection of the converter to the L50 via relay and
SH1 helix allow it to amplify relatively small conformational
changes of the motor domain that result from changes in nucleo-
tide state and actin attachment (Mesentean et al., 2007).
The neck domain extension of the myosin-2 head region is
composed of two IQ motifs containing the consensus sequence21, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1911
Figure 1. Architecture of the Actomyosin
Complex
Domain architecture (A) and topology map (B) of
complex formed by F-actin and b-cardiac myosin-
2 head fragment. Subdomains of myosin are
color-coded: blue, N-terminal domain; red, upper
50 kDa domain; yellow, lower 50 kDa domain;
purple, converter; gray, neck region; green,
myosin light chain-1; cyan, myosin light chain-2.
Subdomains of actin are color-coded: teal, sub-
domain 1; pink, subdomain 2; orange, subdomain
3; green, subdomain 4. Interactions between
myosin and actin are indicated by green dashed
lines.
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Review[I,L,V]QxxxRGxxx[R,K] and providing the binding site for an
essential light chain (ELC) and a regulatory light chain (RLC).
The ELC occupies the binding site closest to the motor domain,
whereas the RLC occupies the second site. Typical IQ motifs
consist of 25 amino acids, forming an uninterrupted a helix that
is distinctly amphiphilic (Espreafico et al., 1992). As velocity
and step size are linearly related to the length of the resulting
elongated and rigid structure, the neck domain is thought to
act as a lever arm that amplifies the movement generated in
the motor domain (Anson et al., 1996; Ruff et al., 2001; Uyeda
et al., 1996).
The neck domain is followed by an extended rod domain
(1,100 amino acids) that mediates the association of the two
MHC-2 s, through the formation of a long, parallel a-helical coiled
coil. Additionally, intermolecular interactions between the rod
domains of the resulting hexameric myosin-2molecules mediate
the assembly of bipolar filaments. Parallel and antiparallel inter-
actions between neighboring myosin-2 molecules are critically
supported by two relatively short regions in the C-terminal part
of the rod domain, which display an unique electrostatic profile
that is composed of short alternating segments of negative
and positive charge (Nakasawa et al., 2005; Rosenberg et al.,
2008; Sohn et al., 1997). The axial staggering between myosin-
2 molecules within a filament appears to be related to a 28-res-
idue periodicity of positive and negative charge that extends
along the rest of the a-helical-coiled coil (Atkinson and Stewart,
1992; McLachlan and Karn, 1982). A short C-terminal segment,
termed the tailpiece of up to 47 amino acids in length is also crit-
ical for filament assembly (Ronen and Ravid, 2009).1912 Structure 21, November 5, 2013 ª2013 Elsevier Ltd All rights reservedIn addition to the class 2 myosins, the
superfamily of myosin motors comprises
at least 34 classes of so-called un-
conventional myosins. They share the
generic globular motor domain with con-
ventional myosins, which allows them to
drive motile processes such as endocy-
tosis, intracellular transport, the forma-
tion of cell surface protrusions, the gating
of ion channels, cell motility, and adhe-
sion, and to influence the organization of
the actin-based cytoskeleton (reviewed
in Hartman et al., 2011; Preller and Man-
stein, 2012). Unconventional myosins
display great diversity in domain architec-
ture. They vary in size from isoforms thatbarely exceed the size of the generic motor domain to isoforms
exceeding the size of conventional myosin, due to the presence
of extensions with complex domain architecture. Their neck
region is formed by one to seven IQ motifs, which bind calmod-
ulin or calmodulin-like light chains. The exact nature of the
interacting light chains remains to be elucidated for most uncon-
ventional myosins.
Approximately 20 different types of protein domains con-
tribute to the diversity found in unconventional myosins. Their
function can include the association of myosins with each other,
anchoring myosins for movement relative to actin filaments,
specifying binding to different cargoes, and the regulation of
intrinsic and extrinsic protein domains. Class 3 myosins contain
an active serine/threonine kinase domain at their N terminus.
Autophosphorylation of a site in the motor domain inhibits
ATPase activity and reduces actin affinity (Quintero et al.,
2010). Class 9 myosins contain in their tail region a domain
with Rho GTPase-activating protein activity that negatively reg-
ulates the small GTP-binding protein Rho (Mu¨ller et al., 1997). In
addition to the classification of myosin motors based on
sequence analysis, their biochemical and kinetic properties
have been used to define four different types of myosins with
(1) fast, (2) slow, (3) strain sensor-like, and (4) processive motor
properties (Bloemink and Geeves, 2011). Several functional
types can be found within a single phylogenetically defined
class, e.g., fast, slow, and strain sensor-like class 2 myosins
have been described.
The primary binding partner of myosin is the bipolar actin fila-
ment, which can be described as two separate right-handed
Figure 2. The Chemomechanical Actomyosin ATPase Cycle
The actin filament is shown as brown surface representation. Myosin S1 is
depicted as blue ribbon diagram. The two myosin light chains are colored
green and cyan, respectively. The structural states during the power stroke are
not characterized yet and therefore shown as silhouettes. A, actin; M, myosin
in the down conformation; M*, myosin in the up conformation; T, ATP; D, ADP;
Pi, inorganic phosphate.
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Reviewhelical strands, wrapped around each other with a rise of 27.5 A˚
per monomer, and 13 molecules and six turns per 360 repeat
(Fujii et al., 2010; Holmes et al., 1990, 2003). Filamentous actin
(F-actin) has a dual function in its interaction with themyosin mo-
tor: it provides support as a track and acts as a release factor for
the hydrolysis products. Moreover, stereospecific binding of
myosin and the inherent polarity of the actin filament form the
basis of directional movement. Mammals produce six actin
isoforms (skeletal and cardiac a-actin, cytoplasmic b-actin,
cytoplasmic and smooth-muscle g-actin). Actin isoforms are
essential for awide range of physiological functions. Their impor-
tance and high degree of functional specialization is indicated by
experiments indicating that the isoactins cannot substitute for
each other (Fyrberg et al., 1998; Kaech et al., 1997; Khaitlina,
2001; Kumar et al., 1997; Mounier et al., 1997). The four muscle
actin isoforms are restricted to tissues with high tonic activity
such as heart, skeletal, and smooth muscle (Tondeleir et al.,
2009). Cytoplasmic b-actin and g-actin are ubiquitous and play
a pivotal role in cell motility, intracellular transport, cell shape
maintenance, cytokinesis, and mitosis (Dugina et al., 2009).
They undergo spatial and temporal segregation, thereby contrib-
uting to the creation of intracellular compartments with an intri-
cate and dynamic yet tightly regulated structural design (Chesar-
one and Goode, 2009; Gunning et al., 2008; Hoock et al., 1991;
Pollard and Borisy, 2003; von Arx et al., 1995). Consequently,
myosin motors do not interact with bare F-actin in their proper
cellular environment but function in the context of sophisticated
actin-based complexes with highly diverse bioarchitecture.
These include the sarcomeres of smooth, striated, and cardiac
muscle, the tight bundles of actin filaments found in microvilli,Structurestereocilia, stress fibers and filopodia, submembranous net-
works, and highly dynamic and integrated structures such as
those found in focal adhesions and the cleavage furrow. Allo-
steric triggers such as differences in actin isoform composition
can contribute to the modulation of myosin activity and thereby
to the spatial and temporal regulation of cytoskeletal dynamics
(Mu¨ller et al., 2013).
Chemomechanical Coupling
Critically important elements driving the conversion of chemical
energy provided by the hydrolysis of ATP to force andmovement
are the near irreversible and thus highly directional nature of the
ATPase cycle, very large changes in F-actin affinity depending
on whether the nucleotide is ATP or ADP, and a strong reciprocal
relationship between the affinity of the myosin motor for F-actin
and ATP. Typically, strong binding to F-actin reduces the affinity
for ATP 10,000-fold and vice versa. Moreover, the myosin-
ADP.Pi and myosin-ATP states share a similarly low affinity for
F-actin. In the absence of F-actin, the myosin-ADP.Pi complex
is a thermodynamically unstable but long-lived intermediate,
with a half-life in the range of tens of seconds. The exchange fac-
tor activity of F-actin accelerates the release of the hydrolysis
products and greatly reduces the half-life of the myosin-ADP.Pi
complex. Key properties defining the type of mechanical activity
displayed by myosins arise from the exact nature of actomyosin
interaction. The duty ratio, thermodynamic coupling of actin and
nucleotide binding tomyosin, and the degree of strain-sensitivity
of the ADP release step depend on its exact effect on the life-
time of the A.M.D.Pi and A.M.D states and the fraction of the total
cycle time spent in each of these states. Progression from the
A.M.D.Pi to the A.M.D state is best described as a multistep
process involving the transition from low to high actin affinity
and high to low ADP affinity. Strengthening of the interaction
with F-actin is accompanied by the build-up of mechanical strain
in the myosin motor and its subsequent release in form of the
power-stroke. The exact order of the accompanying conforma-
tional changes, Pi release, and power-stroke may vary between
myosin isoforms.
Amajor problem from the structural biology perspective is that
the actomyosin complexes is refractory to crystallization, which
renders the critical intermediates between the A.M.D.Pi and
A.M.D states of the actomyosin ATPase cycle inaccessible to
direct structural characterization (Figure 2). Readily accessible
for detailed structural analysis are only stable nucleotide-state
intermediates of the myosin motor domain obtained in the
absence of actin (Rayment et al., 1993b). Rigor-like structures
with the lever arm pointing downward, in the direction of the
barbed end of actin, and a closed cleft are reproducibly obtained
in the absence of nucleotides and multivalent anions (Coureux
et al., 2003; Reubold et al., 2003). The resulting atomic models
fit with minimal adjustments in subnanometer-resolution cryo-
EMdensities obtained for the actomyosin rigor complex (Geeves
and Holmes, 2005). High-resolution X-ray structures of the
myosin motor domain trapped in pre-power stroke states, with
the lever arm up and an open cleft, are reproducibly obtained
in the presence of ADP$AlF4
, ADP$VO4, or ADP$VO3. Struc-
tures of the complexes with ADP$AlF4
 and ADP$VO4 clearly
mimic the transition state of the ATP hydrolysis reaction with a
pentavalent, bipyramidal vanadium or aluminum atom21, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1913
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Review(Dominguez et al., 1998; Smith and Rayment, 1996). In contrast,
structures of the complex with ADP$VO3 resemble more the
reactant state (ATP state) with a tetragonal conformation of the
vanadium atom (Fedorov et al., 2009). Therefore, conformational
states of the myosin motor that define extreme positions in re-
gard to nucleotide and actin affinity as well as lever arm position
are well-defined by these structures.
Driven bymethodological and instrumental progress, the early
adaptation of hybrid approaches in the actomyosin field bears
fruit for the analysis of the structure of F-actin and its complexes
(Behrmann et al., 2012; Fujii et al., 2010; Holmes et al., 1990;
Rayment et al., 1993a; Schro¨der et al., 1993). Hybrid approaches
are beginning to yield detailed information about the structure of
rigor-like intermediates of the myosin motor in complex with F-
actin. Moreover, they allow including and addressing the role
of regulatory components of the actomyosin system. Pseudo-
atomic models of the actomyosin rigor complex, obtained by
rigid-body docking atomicmodels of F-actin, themyosin-1Emo-
tor domain, and tropomyosin into subnanometer-resolution
cryo-EM densities followed by flexible fitting, explain the me-
chanical robustness of the protein interface and the tropomy-
osin-dependent modulation of myosin binding to F-actin (Behr-
mann et al., 2012). The models show a cogwheel-like
interaction of myosin with two neighboring actin molecules
involving a contact surface that exceeds 1,800 A˚2. The primary
contact site involves SD1 and SD3 of actin and loop2, helix
HW, loop4, and the cardiomyopathy loop of myosin (Figure 1).
Here, electrostatic interactions and salt bridge formation appear
to contribute to the formation of a double sandwich composed of
the negatively charged N terminus of actin (D1, E2, D3, E4), posi-
tively charged residues in loop2 and on helix HW, a negatively
charged loop from actin SD1 (D24, D25), and positively charged
residues on the CM loop. Salt bridge formation plays also a role
in mediating the contact between loop3 and SD1 of the next
lower actin along the long pitch helix. Other extensions of the pri-
mary contact site are mainly mediated by hydrophobic interac-
tions. These include the L50 helix-loop-helix motif protruding
into a cavity formed by SD1 and SD3 of the upper and SD2 of
the lower actin and apolar residues on the CM loop that are in
contact with hydrophobic regions on actin SD1 and SD3 (29–
31, 329–334) (Behrmann et al., 2012; Lorenz and Holmes,
2010). Myosin isoform-specific modifications of the actomyosin
interface include large changes in the length of surface loops and
in particular of loop2. However, charge and charge density dis-
tribution in actin binding regions appear highly conserved and
this includes the N-terminal actin-binding part of loop2 (Furch
et al., 2000; Odronitz and Kollmar, 2007).
The transition from rigor-like to prepowerstroke state involves
the formation of a hydrolysis competent active site, which ap-
pears to be tightly linked to the movement of converter and lever
arm from the down to the up position and the opening of the large
cleft with the associated spatial separation of regions that are
involved in tight actin binding. Myosin lacks a high-affinity nucle-
otide binding site in the rigor-state. The nucleotide sensing loops
have moved outward eliminating any potential for interactions
between the nucleotide g-phosphate and the myosin, as well
as almost all coordination, either direct or indirect, between the
protein and the Mg2+ ion. The loss of Mg2+ coordination com-
bined with the positioning of switch I and II greatly facilitate the1914 Structure 21, November 5, 2013 ª2013 Elsevier Ltd All rights rerelease of ADP. The availability of Mg2+-ATP in millimolar con-
centration in the cellular environment allows efficient progres-
sion through the ATPase cycle. Contact of the g-phosphate
group of ATP with the P loop triggers a sequence of large confor-
mational changes (Cecchini et al., 2008; Coureux et al., 2004).
The central role played by the g-phosphate in the interaction
with the nucleotide-binding loops explains why ATP but not
ADP can induce the ensuing changes leading to low actin affinity
and the recovery-stroke. The P loop and both switch I and switch
II are drawn in close contact with the nucleotide. Together, these
movements of the active site loops establish an extensive
network of hydrogen bonds stabilizing g-phosphate binding
and the coordination of theMg2+ ion (Coureux et al., 2004). Addi-
tionally, the movement of the nucleotide-binding loops is
coupled directly to the seven-stranded b sheet resulting in a
change in its twist and opening of the large cleft. Thereby,
changes of nucleotide binding loop structures are coupled to
large movements of the actin binding region that lead to the
dissociation of the actomyosin complex.
Moreover, the inward movement of switch II, the repositioning
in the central b sheet and associated changes transmitted to the
relay helix and the SH1-SH2 region trigger the recovery-stroke
bringing the converter domain and lever arm to an up position.
The establishment of a tight network of hydrogen bonds in the
final ATP-myosin complex is concomitant with the formation of
a proper active site (Fedorov et al., 2009; Smith and Rayment,
1996). The hydrolysis reaction allows the ATPase cycle to
advance to the myosin-ADP-Pi intermediate. Rebinding of the
myosin motor domain to F-actin can now induce an apparent
reversal of the sequence of conformational changes that are
induced by ATP binding. The productive built-up of mechanical
strain can only occur with myosin bound to F-actin. This distin-
guishes the power-stroke and recovery-stroke parts of the
ATPase cycle. The associated structural differences are the ob-
ject of further studies. The reformation of a high-affinity actin
binding site is thought to occur concomitant with the built-up
of mechanical strain. The disruption of the tight network of
hydrogen bonds in the active site, the outward movement of
the nucleotide binding loops and product release accompany
strain release upon the downward movement of the lever arm
during the power-stroke and return themotor to a rigor-like state.
Molecular Engineering of Myosin
The actomyosin system has unique features that make it an
attractive target for studying structure-function relationships in
isolated proteins and protein complexes with the help of molec-
ular engineering approaches (Manstein, 2004). A wide range of
myosin motors can be readily produced in recombinant form
(Ito et al., 2003; Manstein et al., 1989; Pato et al., 1996; Sata
et al., 1996; Srikakulam and Winkelmann, 1999; Zhu et al.,
1996). Their function can be studied at the level of single mole-
cules, molecule ensembles, in vitro and in vivo (Belyantseva
et al., 2005; Egelhoff et al., 1990; Geeves et al., 1984; Ishijima
et al., 1998; Ko¨hler et al., 2002; Nenasheva et al., 2011;
Zhang et al., 2004). Chemical, spectroscopic, and mechanical
changes can be used to monitor their enzymatic competence.
Based on the observation that conformational changes during
the transition between different nucleotide states do mostly
correspond to rigid-body rotations of secondary and tertiaryserved
Figure 3. Ribbon Diagram of the Myosin-2
Structure Showing the Binding Sites of Four
Known Small Effector Molecules
The binding sites of the inhibitors were identified
by X-ray crystallography (Protein Data Bank [PDB]
codes 1YV3, 2JHR, 2XEL, 2XO8, 4AE3). Note that
Ammosamide 272 binds to two binding sites in the
myosin motor domain: it additionally interacts with
the pseudilin binding site. The omecamtiv me-
carbil binding site was derived from crosslinking
experiments (Malik et al., 2011).
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Reviewstructure elements, the motor domain can be regarded as con-
sisting of communicating functional units with substantial move-
ment occurring in only a few residues (Dominguez et al., 1998;
Holmes, 1998). The inferred modular nature of the myosin motor
domain and the central importance of the regions connecting
individual modules facilitate the dissection of their impact on
functional features such as the stride of individual power-
strokes, the extent to which the myosin motor can generate
movement versus force, and the direction of movement.
A linear relationship between step size or velocity and the
length of the neck region, which is implied by a lever arm mech-
anism, was observed with several engineeredmyosin constructs
(Anson et al., 1996; Ruff et al., 2001; Uyeda et al., 1996). More-
over, protein engineering was successfully employed to turn a
plus-end directed myosin-1 motor into a minus-end directed
motor. This was achieved by rotating the direction of the lever
arm 180 by the insertion of a four-helix bundle between the helix
emerging from the converter and the helix forming part of the
lever arm (Tsiavaliaris et al., 2004). The lever arm hypothesis is
thus well supported by experimental evidence and apparent de-
viations can be explained by the contribution of unconventional
neck regions to lever arm length. Two types of unconventional
lever arm extensions have been characterized in detail. Stable,
single alpha helix (SAH) domains extend the functional length
of the myosin-10 lever arm (Baboolal et al., 2009; Knight et al.,
2005). The lever arm of myosin-6 can be extended by the open-Structure 21, November 5, 2013 ªing of a three-helix bundle and subse-
quent stabilization of the emerging long
a helix by calmodulin binding (Liu et al.,
2011; Mukherjea et al., 2009). Both SAH
domains and extendable three-helix bun-
dles hold some potential as building
blocks for protein engineering projects
(Adamek et al., 2011; Peckham and
Knight, 2009).
The fact that unfolding of the three-he-
lix bundle occurs only upon dimerization
of two myosin-6 monomers is a valuable
reminder that protein function is not
solely governed by the hard-wiring of
rigid functional modules. Enzyme func-
tion can also be greatly altered by the
input of allosteric triggers, such as post-
translational modifications, small-mole-
cule binding, protein-protein interactions,
isoform-specific amino acid substitu-
tions, or mutations. The effects of anallosteric trigger event can change the functional behavior of
single domain proteins but it can as well propagate across multi-
molecular assemblies and filamentous networks. The resulting
changes and the distances over which they are transmitted are
difficult to predict. Therefore, results obtained with perturbed
allosteric systems need to be interpreted with caution and
cannot be equated with the properties of the native enzymes in
their proper cellular context.
Allostery and Mechano-Chemistry
Allosteric communication is a pivotal aspect of the function of
motor proteins, where a perturbation at one site affects a remote
active site. The resulting perturbations can be described to alter
the dominant catalytic pathway by shifting or redistributing the
ensemble of conformations, intermediates and transition states
for any given point along the reaction coordinate (Goodey and
Benkovic, 2008). The large number of allosteric trigger events,
interfering and additive effects due to their cooccurrence, and
their dynamic nature present an enormous challengewhen faced
with the task to decipher an allosteric code. The reductionist
approach that now dominates research in cell and structural
biology has been employed with spectacular success for eluci-
dating the molecular mechanism underlying cellular motility in
general and the function of individual components of the acto-
myosin system in particular (Pollard and Borisy, 2003). To vali-
date allosteric effects and their impact on the function of2013 Elsevier Ltd All rights reserved 1915
Table 1. Summary of the Properties of Allosteric Effectors of Myosin Function
Effector
Abbreviations,
Alternative Names Mechanism of Action Structure (X-Ray) Activity/Potency Reference
2,3-Butanedione
2-monoxime
BDM ATPase rate and force production
decreased inhibition of Pi release
and stabilization of the weakly
actin-bound myosin ADP Pi state
n/a Kiz5 mM (skeletal muscle
myosin-2)
McKillop et al., 1994;
Herrmann et al., 1992;
Higuchi and Takemori,
1989
N-benzyl-p-toluene
sulfonamide
BTS in vitro gliding motility, force
production and ATPase rate
inhibited actin-myosin
interaction weakened and
Pi release suppressed
n/a (binding site proposed
to be in the large internal cleft)
IC50z5 mM (skeletal muscle
myosin-2)
Shaw et al., 2003;
Cheung et al., 2002
Trifluoperazine TFP ATPase rate and in vitro gliding
motility inhibited myosin light
chains are removed at higher
concentrations (1–2 mM)
n/a IC50z40–75 mM (smooth,
nonmuscle, skeletal muscle
myosin-2, myosin-5)
Sellers et al., 2003;
Patel et al., 2000
3-[4-(3-Phenyl-2-pyrazolin-1-yl)
benzene-1-sulfonylamido]
phenylboronic acid
PPBA inhibits myosin allosterically by
stabilizing a ternary myosin
PPBA nucleotide complex
n/a (binding site proposed to
overlap in part with blebbistatin
binding site)
Kiz0.8 mM (skeletal muscle
myosin-2)
Hiratsuka, 2006;
Bobkov et al., 1997;
Hiratsuka, 1994
()-Blebbistatin and
blebbistatin analogs
— myosin trapped in a weak
actin-binding prepower stroke
ADP Pi state Pi release-inhibited
hydrophobic allosteric binding
site at the apex of the large
internal cleft, <4 A˚ away from
switch-1 and switch-2 of the
active site (PDB: 1YV3, 3BZ7,
3BZ8, 3BZ9, 3MJX)
IC50 = 0.5–2 mM (skeletal
and nonmuscle myosin-2)
Lucas-Lopez et al., 2008;
Allingham et al., 2005;
Kova´cs et al., 2004;
Limouze et al., 2004;
Straight et al., 2003
MyoVin-1 — ATPase rate decreased ADP
release-inhibited
n/a Ki = 6.3 mM (Gg myosin-5) Islam et al., 2010
Halogenated pseudilins
(pentabromopseudilin,
pentachloropseudilin,
tribromodichloropseudilin)
PBP, PClP,
TBDClP
ATP binding, hydrolysis and ADP
dissociation-inhibited, coupling
between actin and nucleotide
binding sites is reduced Active
site is affected through a signal
relay path as well as global
protein dynamics
allosteric binding site close to the
actin-binding region and the apex of
the large internal cleft 16 A˚ away
from the active site (PDB: 2XO8,
2XEL, 2JHR)
PBP: IC50 = 1.2 mM
(Gg myosin-5a)
PClP: IC50 5 mM (Rn
myosin-1b and myosin1c)
TBDClP: IC50 = 47.2 mM
(Dd myosin-2)
Preller et al., 2011;
Chinthalapudi et al., 2011;
Fedorov et al., 2009
Ammosamides — n/a two allosteric binding sites: (1)
binding site of halogenated
pseudilins; (2) binding site near
activation loop (PDB: 4AE3)
low mM activity (bind to a wide
range of myosins) determined
by immunoprecipitation and
staining with fluorescent
ammosamide conjugates
Hughes et al., 2009
Halogenated phenols
(2,4,6-Triiodophenol)
TIP Bobel-24
AM-24
ATPase activity reduced n/a (proposed to bind to blebbistatin
or halogenated pseudilin binding site)
Ki1 = 0.8 mM and Ki2 = 37 mM
(Hs myosin-6)
Heissler et al., 2012
Omecamtiv mecarbil CK-1827452 transition from weak to strong
actin-bound state accelerated
and Pi release rate increased
at submicromolar Ca2+-ion
concentrations
n/a (proposed binding site between
N-terminal domain and converter,
near residue Ser148)
EC50 = 2.3 mM (b-cardiac
myosin-2)
Malik et al., 2011;
Morgan et al., 2010
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Figure 4. Allosteric Coupling between Actin and Nucleotide Binding Sites
Schematic depiction of the signal relay path that has been identified by comparative crystallographic analysis of myosin-2 X-ray structures in complex with
pseudilin inhibitors (Chinthalapudi et al., 2011, Preller et al., 2011, Fedorov et al., 2009). Binding of the halogenated pseudilins to the allosteric site leads
to conformational changes of the amino acid residues along the relay path and thereby, interferes with proper positioning of the lytic water in the active site for an
in-line attack to facilitate ATP hydrolysis (indicated by the green star).
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Reviewsupramolecular complexes in the cellular environment, an
extension of the reductionist approach is required that incor-
porates accurate allosteric awareness (AAA). Difficulties in pro-
ducing the correct combinations of protein isoforms for detailed
biochemical and structural characterization must be overcome
in this context for the accurate determination of rate and
equilibrium constants, structural features, forces, and velocities.
Experimentally determined biochemical and physical parame-
ters need to be validated by comparison with the results from
cell or tissue-based studies that analyze the exact same com-
plexes. The same holds true when these models are extended
to include the effects of posttranslational modifications or
disease causing mutations.
Myosin-Based Therapeutic Approaches
Changes in the abundance or functional competence of specific
myosin isoforms have been implicated in the development of
severe diseases, including neurodegeneration, heart failure,
diabetes, and cancer (Bond et al., 2013). Potent and selective
modulators of myosin activity and stability hold therefore great
potential as therapeutic agents. In the case of myosin motors,
small molecule-based approaches targeting the active site are
not practicable. The active site is not only highly conserved
within the myosin family but among P loop nucleotide triphos-
phatases such as microtubule-based motor proteins, protein
kinases, and G-proteins (Odronitz and Kollmar, 2007; Saraste
et al., 1990).
In contrast to the high degree of conservation observed at
active sites, allosteric mechanisms and sites are less well
conserved (Kuriyan and Eisenberg, 2007; Salvesen and Riedl,
2007; Schweizer et al., 2007). Myosinmotor activity is modulated
by a number of allosteric trigger events including protein-protein
interactions and metabolite binding (Katayama et al., 2010;
Lowey and Trybus, 2010; Sellers and Knight, 2007). At leastStructurefour nonoverlapping binding sites for drug-like modulators of
myosin function have been identified (Figure 3). Accordingly, a
number of allosteric effectors showing preferred interactions
with one or a restricted set of myosin isoforms have been
described (Table 1) (Allingham et al., 2005; Chinthalapudi et al.,
2011; Fedorov et al., 2009; Heissler et al., 2012; Islam
et al., 2010; Malik et al., 2011; Preller et al., 2011; Straight
et al., 2003). Allosteric inhibitors of nonmuscle myosin-2 (NM2)
function have been described to hold therapeutic potential by
blocking the invasiveness of tumor cells in an NM2A-dependent
manner (Derycke et al., 2011; Duxbury et al., 2004). Modulation
of NM2B by small molecule drugs alters myofibroblast migration
and infiltration, thereby affecting the healing and remodeling of
the heart (van den Borne et al., 2010). Activation of b-cardiac
myosin by the use of small molecules has been suggested
to provide a promising therapeutic approach for systolic heart
failure (Cleland et al., 2011).
As myosins perform their work always within the framework of
supramolecular complexes and orthogonal dipolar interactions,
it is of utmost importance to characterize their interactions with
drug-like molecules in the context of an AAA approach (Paulini
et al., 2005). Moreover, cooperative effects can greatly enhance
the physiological consequence of a small molecule-induced allo-
steric perturbation across a complex, filament or network. Point
mutations in the b-cardiac myosin heavy chain are among the
most common causes of familial hypertrophic cardiomyopathy
(FHC) (Ho, 2010). Themutations can affect myosin function, ther-
mal stability, and proteolytic degradation (Cammarato et al.,
2008). In the case of myosin, the negative consequences of
reduced protein stability and the resulting increased misfolded
protein-load are amplified by the formation of roadblock-like,
strongly-bound complexes with the actin filament tracks
(Murphy and Spudich, 1999) and a permanent activation of the
troponin-tropomyosin system (Hill et al., 1983). Therefore, small21, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 1917
Figure 5. Modulation of the Troponin-Tropomyosin Regulated
Cardiac Actomyosin by Small-Molecule Effectors as a Function
of Calcium Concentration
(A) Typical changes in the force/pCa relationship upon addition of the allosteric
activator EMD 57033 to cardiomyocytes. Experiments were performed under
isometric conditions with cardiomyocytes isolated from adult pig ventricle in
the absence (n = 5) and presence of 5 mM EMD 57033 (n = 6). Results are
shown as mean ± SEM.
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Reviewmolecules that increase thermal stability and prevent myosin
misfolding can have wide-ranging therapeutic benefits for the
treatment of myopathies.
Small molecules that stabilize an already folded protein by the
formation of a tight interaction network are termed pharmaco-
logical chaperones. Most of the pharmacological chaperones
directed at other types of enzymes are active site ligands (Ringe
and Petsko, 2009). In the case of myosin, the four structurally
characterized allosteric binding pockets provide a good starting
point for the development of compounds displaying tight and
specific binding. Whether the resulting compounds confer stabi-
lization, activation of or inhibition upon binding to these sites de-
pends on the exact nature of their interactions. This can be illus-
trated by the allosteric binding site for halogenated pseudilins,
which is located close to the top of the large 50 kDa cleft and
16 A˚ away from the nucleotide-binding site (Figure 3). Binding
of halogenated pseudilins is mediated both through hydrogen
bonds and hydrophobic interactions. Crucial hydrogen bonds
are formed with either of the two polar groups, the hydroxyl
group of the phenol ring as well as the amino group of the pyrrole
ring. Further interactions include amino acid residues Ser260,
Lys265, Ala420, Ala424, Arg428, Leu431, Asp590-Leu592,
Ile617-Ser619, and at least two water molecules (numbering re-
fers toDictyosteliummyosin-2). Number, size, and polarity of the
halogen substituents as well as the polarity of the binding pocket
in different myosin isoforms greatly affect the specificity and po-
tency of the compounds (Preller et al., 2011). Residue Lys265
was found to play a pivotal role for the mechanism of inhibition
(Chinthalapudi et al., 2011); upon binding of halogenated pseudi-
lins and formation of a hydrogen bond to Lys265, the amino acid
side chain rearranges by 3–4 A˚, which constitutes the starting
point for a cascade of small conformational changes along the
allosteric relay path that concludes in the incapacity of myosin
to keep the lytic water for ATP hydrolysis and thus, directly
affects the enzyme’s active site (Figure 4). Compounds that
display tight binding to this site without involvement of Lys265
are likely to act as pharmacological chaperones.
Cardiac myosin activators typically accelerate the rate of the
phosphate release step following ATP hydrolysis (Malik et al.,
2011). This results in increased ATP turnover and faster transition
to strongly actin-bound states. As the population of force-pro-
ducing myosin motors increases, more cross-bridges can form
during systole, leading to increased systolic ejection time and
stroke volume. Moreover, stronger binding of myosin to actin re-
duces the regulatory efficiency of the troponin-tropomyosin
complex. The result is an increase in ATP turnover at maximum
calcium concentration as well as a shift of the force/pCa relation
to lower calcium concentrations (Figure 5A). These apparent
changes in calcium sensitivity are brought about only by(B) The addition of 20 mM omecamtiv mecarbil to troponin-tropomyosin
regulated actin-myosin purified from bovine heart leads to an increase in
ATPase rate at pCa < 6 and a decrease at pCa > 6 (reproducedwith permission
from Malik et al., 2011). Results are shown as mean ± SD.
(C) Change in the ATPase/pCa relationship upon addition of 10 mMEMD57033
to canine heart myofibrils, prepared as described previously (Solaro et al.,
1993). Physiological changes in Ca2+ concentration occur in the pCa range
57. Omecamtiv mecarbil and EMD 57033 bind to the same region in the
myosin motor domain (M.B. Radke, M.H. Taft, M. Preller, and D.J. Manstein,
unpublished data). Solid line (control); dashed line (plus allosteric modulator).
Results are shown as mean ± SEM.
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Reviewmyosin-induced cooperative effects, which are communicated
throughout the thin filaments of cardiac muscle and not by
changes in the calcium affinity of the regulatory proteins (Kraft
and Brenner, 1997; Solaro et al., 1993).
The benefit of this type of myosin-dependent inotropic agent
lies in improved myocardial contractility without accompanying
increases in the rate of contraction and myocardial oxygen con-
sumption. However, without change in heart rate, increased sys-
tolic ejection timemust occur at the expense of diastole. This will
cause ischemia, due to reduced ventricular filling and coronary
perfusion. Omecamtiv mecarbil is a small-molecule that is
currently undergoing tests in the context of a clinical trials pro-
gram for the treatment of patients with heart failure. It is well
tolerated, with signs of ischemia only occurring at high-dose
infusion (Teerlink et al., 2011). Although omecamtiv mecarbil is
frequently referred to as an allosteric activator of b-cardiac
myosin, it actually compresses the range over which ATPase
activity and presumably force generation is altered by changes
in pCa. Moreover, it does not induce a shift of the ATPase/pCa
relation to lower calcium concentrations (Figures 5B and 5C).
ATP turnover is actually reduced at calcium concentrations in
the micromolar range and increased in the sub-micromolar
range (Malik et al., 2011).
As the type of weak inhibition exerted by omecamtiv mecarbil
at calcium concentrations in the upper physiological range iswell
tolerated, it appears worthwhile to consider a wider range of allo-
steric myosin effectors for the treatment of patients with genetic
heart diseases. Imbalanced force generation among neighboring
cardiomyocytes, due to the unequal allelic expression of mutant
and wild-type b-cardiac myosin, appears to be an important
trigger of cardiomyopathies in some patients (Kraft et al., 2013;
Tripathi et al., 2011). As the extent to which the enzymatic activity
of wild-type and mutant proteins is affected by non-competitive
binders is not linearly related, small molecule-based approaches
promise to reduce the mismatch in force production with bene-
ficial outcome even if this entails weak inhibition of overall
contractility. Allosteric propagation and the contribution of
orthogonal dipolar interactions to molecular recognition make
it appear feasible that b-cardiac myosin can be used as thera-
peutic target, even in situations where imbalanced force
generation among neighboring cardiomyocytes is caused by
mutations in other components of the sarcomere such as actin,
titin, or tropomyosin.
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